They are not going to "fall on their face" but will we hear anything we don't already expect to hear? No. 2 years ago, we received top line data that showed Anavex's AD therapy slows dementia progression better than any other therapy, and 16 months ago we learned that it massively slows brain volume loss. What more do you want? If that didn't move the needle - and it didn't - then what do you expect to happen tomorrow? Only regulatory agencies allowing 2-73 to progress matters right now with respect to this program. The only question that matters now is: will the EMA and (later) the FDA grant exceptions based on one strong P2/P3 data set?
Market Data 
Markets 
AI
